16681-71-3

Usage

Uses

Used in Pharmaceutical Industry:
1-Methyl-1H-1,2,3-triazole-4-carboxylic acid is used as a reactant in the preparation of click chelators for platinum-based anticancer drugs. These chelators play a crucial role in enhancing the stability, solubility, and bioavailability of platinum drugs, which are widely used in the treatment of various types of cancer. The incorporation of 1-Methyl-1H-1,2,3-triazole-4-carboxylic acid into click chelators allows for the formation of more effective and targeted anticancer therapies.

Upstream product

• 13273-53-5 4-bromo-1-methyl-1H-1,2,3-triazole 
• 74-88-4 methyl iodide 
• 116057-94-4 1-Methyl-4-trinitromethyl-1,2,3-triazole 
• 624-90-8 methyl azide 
• 471-25-0 Propiolic acid 
• 16681-69-9 1-methyl-1H-1,2,3-triazole-4-carbaldehyde 
• 39039-48-0 1-methyl-1H-1,2,3-triazole-4-carboxylate d'ethyle 

Downstream Products

• 16681-65-5 1-methyl-1,2,3-triazole 
• 216065-41-7 4-(N-Bocamino)-1-methyl-1,2,3-triazole 

Relevant academic research and scientific papers

Preparation method of 1-subtituted-1H-1,2,3-triazole-4-carboxylic acid

The invention provides a preparation method of 1-subtituted-1H-1,2,3-triazole-4-carboxylic acid. The preparation method includes the following steps: 1-substituted-4,5-dibromo-1H-1,2,3-triazole is added to an isopropylmagnesium chloride, such that 1-substituted-4-bromo-1H-1,2,3-triazole is obtained through a reaction; an isopropylmagnesium chloride-lithium chloride complex is added directly, such that a mixture of 1-substituted-1H-1,2,3-triazole-4-carboxylic acid and 1-substituted-4-bromo-1H-1,2,3-triazole-5-carboxylic acid is obtained; a base and iodomethane are added to the mixture, such that methyl 1-substituted-4-bromo-1H-1,2,3-triazole-5-carboxylare is obtained through a reaction; the aqueous layer is adjusted with hydrochloric acid until a pH value is 1-5; extraction is carried out with an organic solvent, and drying and concentration crystallization are carried out, such that 1-substituted-1H-1,2,3-triazole-4-carboxylic acid is obtained. The method is suitable for industrial production, and has a great application value.

FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.